eligibility_summary
Include: Adults ≥18 with recurrent glioblastoma (incl. WHO grade 4 astrocytoma), KPS ≥50, life expectancy ≥12 weeks, women of childbearing potential with negative pregnancy test, informed consent. Exclude: allergy to study drugs, serious heart/lung/liver/other organ disease, uncontrolled hypertension/crisis/encephalopathy, other major CNS disease or aggressive cancer, long-term immunosuppression/high-dose steroids, live/attenuated vaccine or unrelated surgery ≤4 weeks pre-apheresis, infection or unexplained fever at apheresis/infusion.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06616727 tests SNC109, an autologous chimeric antigen receptor T-cell (CAR‑T) therapy for recurrent glioblastoma. Intervention: patient-derived T cells are genetically engineered ex vivo to express a CAR recognizing an unspecified GBM-associated surface antigen, then reinfused in multiple doses (starting at 5×10^4 CAR+ T cells) with dosing guided by safety/PK. Mechanism of action: antigen-dependent CAR engagement activates T cells (via CAR signaling domains), triggering cytokine release and perforin/granzyme-mediated cytotoxicity to lyse tumor cells. Target cells/pathways: GBM tumor cells expressing the target antigen, T-cell activation pathways downstream of CAR (CD3ζ/co-stimulation not specified).